Musculoskeletal Stem Cell Differentiation via Signaling Pathway Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for musculoskeletal diseases, such as degenerative arthritis and bone fractures, face challenges in efficiently generating sufficient amounts of musculoskeletal stem cells (MSSCs) that can directly differentiate into bone, cartilage, ligaments, and muscles in the body.
Innovation Solution
A culture medium composition comprising noggin, LIF, bFGF, Wnt signaling activator, ERK signaling inhibitor, and TGF-β/activin/nodal signaling inhibitor is used to cultivate musculoskeletal stem cells (MSSCs), which can then be differentiated into specific musculoskeletal tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If mesenchymal stem cells are used for musculoskeletal tissue regeneration, then they can self-renew and differentiate into mesenchymal origin cells, but it is very difficult to attain the MSCs in an amount sufficient for therapeutic application and they cannot directly differentiate into tissues in the body without in-vitro predifferentiation
Solution Approach 1:
The patent changes the differentiation parameters by using specific small molecules (Wnt signaling activator, ERK signaling inhibitor, TGF-β/activin/nodal signaling inhibitor) to control the differentiation process. This enables direct differentiation of pluripotent stem cells into musculoskeletal stem cells in vitro, overcoming the limitation of insufficient MSC availability for therapeutic applications.
Solution Approach 2:
The patent performs preliminary differentiation of pluripotent stem cells into musculoskeletal stem cells in vitro before transplantation. This preliminary action ensures that sufficient numbers of differentiated cells are obtained for therapeutic application, solving the problem of insufficient cell quantity.
2Reliability
If mesenchymal stem cells are transplanted for tissue regeneration, then they can stimulate intrinsic stem cells by secreting biofactors, but they cannot directly differentiate into musculoskeletal tissues in the body
Solution Approach 1:
The patent uses small molecules to change the differentiation parameters of pluripotent stem cells, enabling them to directly differentiate into musculoskeletal stem cells with the capability to form bone, cartilage, tendon, ligament, and muscle tissues. This gives the cells dual functionality: both stimulating intrinsic stem cells and directly differentiating into target tissues.
3Adaptability or versatility
If human embryonic stem cells or induced pluripotent stem cells are used, then they can differentiate into any cell type including skeletal tissues, but the process requires complex differentiation protocols and conditions
Solution Approach 1:
The patent simplifies the complex differentiation protocol by using a combination of small molecules that target specific signaling pathways (Wnt, ERK, TGF-β/activin/nodal). This parameter-based approach converts a multi-step complex protocol into a more straightforward process with defined chemical agents, reducing overall protocol complexity while maintaining the ability to differentiate into any cell type.
Data Source
AI summary
The present disclosure relates to a novel musculoskeletal stem cell (MSSC) differentiated from an ESC (embryonic stem cell) or an iPSC (induced pluripotent stem cell). The musculoskeletal stem cell of the present disclosure can be easily induced from a human embryonic stem cell or a human-derived pluripotent stem cell and can be effectively differentiated not only into bone but also into cartilage, tendon and muscle. Accordingly, it can be usefully used for prevention or treatment of various musculoskeletal diseases.